ArticleInternational journal of clinical and experimental pathology2014
Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- A New Look at the Role of Radiation-Related Epigenetic Mechanisms in Diagnosis and Anticancer Therapies.Cells · 2025Review
- Effects of the Acetyltransferase p300 on Tumour Regulation from the Novel Perspective of Posttranslational Protein Modification.Biomolecules · 2023Review
- Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells.Cancer gene therapy · 2023Article
- NAA60 (HAT4): the newly discovered bi-functional Golgi member of the acetyltransferase family.Clinical epigenetics · 2022Review
- C/EBPβ enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Article
- Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer.Cell systems · 2022Article
- Mass spectrometry-based characterization of histones in clinical samples: applications, progress, and challenges.The FEBS journal · 2022Review
- PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer.Cancer research · 2021Article
- HISTome2: a database of histone proteins, modifiers for multiple organisms and epidrugs.Epigenetics & chromatin · 2020Article
- Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways.Acta pharmacologica Sinica · 2020Article
- Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta-analysis.Experimental and therapeutic medicine · 2019Article
- Review
- The ZZ domain as a new epigenetic reader and a degradation signal sensor.Critical reviews in biochemistry and molecular biology · 2019Review
- Article
- Subcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma.Medicine · 2017Observational
- CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.Haematologica · 2017Article
- P300 promotes migration, invasion and epithelial-mesenchymal transition in a nasopharyngeal carcinoma cell line.Oncology letters · 2017Article
- Article
- CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway.Molecular oncology · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the correlation among p300, CBP and MLL expression and the clinicopathological characteristics in resected SCLC patients.
methodsTwo hundred and twenty-two resected SCLC patients were included in this study. We evaluated p300, CBP and MLL expression by immunohistochemistry.
resultsPatients with high p300 expression had shorter OS and DFS than those with low p300 expression (p = 0.01; p = 0.009, respectively). The patients with CBP-positive tumors had significantly lower OS and DFS than those with CBP-negative tumors (p = 0.005 and p = 0.007, respectively). Moreover, the p300- and CBP-positive (+) group had a significantly poor OS and DFS. The multivariate Cox regression analysis showed that high p300 and CBP expression are independent markers of poor overall survival (p = 0.006; p = 0.017, respectively) in operable SCLC patients.
conclusionsHigh p300 and CBP expression are independent prognostic markers of poor overall survival for resected SCLC patients. The combination of p300 and CBP expression may be useful in identifying patients with increased risks of cancer recurrence of SCLC.
Indexed as
Identifiers
24551300PMC3925924W174118980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.